权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

INTEGRATING GENETICS, ADVERSE EVENTS, AND ADHERENCE TO IMPROVE SMOKING CESSATION

整合遗传学、不良事件和坚持以改善戒烟

基本信息

批准号：
9050661
负责人：
ROBERT C CULVERHOUSE
金额：
$ 19.29万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-04-15 至 2018-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9050661
关键词：
Adherence Adverse effects Adverse event Affect African American American Bupropion CYP2B6 gene Cessation of life Clinical Trials Complex Controlled Clinical Trials Data Development Distress European Exclusion Genes Genetic Genetic Research Genetic Variation Genetic study Genotype Goals Health Health Care Costs Intervention Knowledge Lead Mediating Mediation Mediator of activation protein Metabolism Methodology Modeling Neuraxis Nicotine Nicotine Dependence Nicotinic Receptors Outcome Participant Patients Pharmaceutical Preparations Pharmacological Treatment Pharmacotherapy Placebo Control Play Resources Role Sampling Sampling Studies Smoker Smoking Testing Time Transdisciplinary Tobacco Research Center United States Universities Variant Washington Wisconsin addiction base cigarette smoking cost experience gastrointestinal genetic association genetic predictors genetic profiling genetic variant genome-wide improved individualized medicine medical schools medication compliance nicotine replacement novel premature prevent productivity loss smoking cessation success treatment adherence treatment planning

项目摘要

DESCRIPTION (provided by applicant): Adverse events are common while using medications to assist an attempt to quit smoking (Piper et al. 2009). The possibility of assigning optimal smoking cessation medications based on a patient's genetic profile is rapidly becoming a reality: genetic variants associated with nicotine dependence and metabolism have been demonstrated to have an impact on utility of smoking cessation pharmacotherapy (Chen et al. 2012, Bergen et al. 2013, Falcone et al. 2011) and there is preliminary data to support the idea that these variants are also associated with adverse events attributable to smoking cessation pharmacotherapy (King et al. 2012). The goal of this project is to evaluate the utility of genetic variants to predict adverse events while using nicotine replacement therapy or bupropion to help a smoker to quit. To achieve this goal, we will use adverse event, adherence, cessation outcome, and genotype data from the University of Wisconsin Transdisciplinary Tobacco Use Research Center study (UW-TTURC). The specific aims are (1) to determine associations between genetic variants and adverse events attributable to smoking cessation medications in the UW-TTURC study, focusing on genes previously associated with nicotine dependence (e.g. nicotinic receptor subunit genes CHRNA5 and nicotine metabolism gene CYP2A6), or bupropion metabolism (e.g. CYP2B6), and (2) to determine the extent to which associations between genetic variants and successful smoking cessation are mediated by adverse events and adherence. Results from this study should improve our ability to predict who will experience adverse events due when using particular smoking cessation medications. This knowledge will lead to personalized smoking cessation therapies that will decrease adverse events, improve adherence, and ultimately increase smoking cessation success.